MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Advances and Challenges in Aortic Regurgitation
Epidemiologic trends, current guidelines, and future directions.
By Joanna Bartkowiak, MD; Jonas Lanz, MD; Thomas Pilgrim, MD; and Fabien Praz, MD
The Impact of Thin-Strut, Biodegradable Polymer Stent Designs
How these stent design characteristics may affect PCI outcomes going forward.
By Raffaele Piccolo, MD, and Thomas Pilgrim, MD
BIOSTEMI Evaluates Biotronik’s Orsiro Biodegradable DES at 2 Years
March 22, 2021—The final 2-year outcomes of the BIOSTEMI trial were published by principal investigator Professor Thomas Pilgrim, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions (2021;14;639-648).
24-Month BIOSTEMI Results Support Biotronik’s Orsiro DES in STEMI Patients
March 15, 2021—Biotronik announced that 24-month follow-up data were presented from the BIOSTEMI randomized controlled trial evaluating the company’s Orsiro ultrathin-strut drug-eluting stent (DES) for target lesion failure (TLF) in patients presenting with acute ST-segment elevation myocardial infarction (STEMI).
Emerging Options for Aortic Regurgitation
By Matti Adam, MD, and Jonathan Curio, MD
Biotronik Launches Orsiro DES With Presentations of Data at CRT
March 6, 2019—Biotronik announced that 3-year outcomes from the BIO-RESORT randomized controlled trial were presented by Clemens von Birgelen, MD, as late-breaking clinical data at CRT 2019, the Cardiovascular Research Technologies annual meeting held March 2–5 in Washington, DC.
Current Trends in PCI
By Ted E. Feldman, MD, MSCAI, FACC, FESC
Biotronik’s Orsiro Mission BP-DES Approved and Launched in the United States
September 30, 2021—Biotronik announced it received FDA approval of its Orsiro Mission bioabsorbable polymer coronary drug-eluting stent system (BP-DES).
Enrollment Begins in United States for BIOFLOW-V Study of Biotronik's Orsiro Hybrid DES
June 18, 2015—Biotronik announced that the first patient in the United States has been enrolled in the BIOFLOW-V clinical study, which is evaluating the safety and effectiveness of the company’s Orsiro hybrid drug-eluting stent (DES).
Treating Coronary Disease in the TAVR Patient
Making the case for managing CAD in patients undergoing TAVR.
By Jubin Joseph, MA, BMBCh, and Simon R. Redwood, MD
Contemporary Assessment of Alternative Access Routes for TAVR
A summary of alternative access options to transfemoral access for TAVR procedures.
By Shane P. Prejean, MD; Mustafa I. Ahmed, MD; and Kyle W. Eudailey, MD
Enrollment Completed in BIOFLOW-IV Study of Biotronik's Hybrid DES
February 4, 2015—Biotronik announced the completion of patient enrollment for the BIOFLOW-IV study, which is intended to support Japanese government approval of the company’s Orsiro hybrid drug-eluting stent (DES).
